Martina Del Monte
Overview
Explore the profile of Martina Del Monte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
10
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Serapide F, Serraino R, Spadafora L, Bernardi M, Brucci G, Cattardico G, et al.
J Antimicrob Chemother
. 2025 Feb;
PMID: 39995279
Objectives: Bloodstream infections (BSIs) due to vancomycin-resistant Enterococcus spp. (VRE) are considered a predictor of mortality among frail patients. The aim of this study was to evaluate the risk factors...
2.
Guaraldi G, Milic J, Renzetti S, Motta F, Cinque F, Bischoff J, et al.
AIDS
. 2024 Apr;
38(9):1323-1332.
PMID: 38597416
Objective: People with HIV (PWH) have high risk of liver fibrosis. We investigated the effect of weight gain and metabolic dysfunction-associated steatotic liver disease (MASLD) on liver fibrosis dynamics. Design:...
3.
Meschiari M, Kaleci S, Del Monte M, Dessilani A, Santoro A, Scialpi F, et al.
Antimicrob Resist Infect Control
. 2023 Nov;
12(1):126.
PMID: 37957773
Background: Vancomycin-resistant enterococcus (VRE) was the fastest growing pathogen in Europe in 2022 (+ 21%) but its clinical relevance is still unclear. We aim to identify risk factors for acquired...
4.
Guaraldi G, Milic J, Barbieri S, Marchio T, Caselgrandi A, Motta F, et al.
Sci Rep
. 2023 Jun;
13(1):8956.
PMID: 37268716
The objective of this study was to characterize frailty and resilience in people evaluated for Post-Acute COVID-19 Syndrome (PACS), in relation to quality of life (QoL) and Intrinsic Capacity (IC)....
5.
Mussini C, Cozzi-Lepri A, Meschiari M, Franceschini E, Burastero G, Faltoni M, et al.
Viruses
. 2023 Feb;
15(2).
PMID: 36851508
Background: Treatment guidelines recommend the tocilizumab use in patients with a CRP of >7.5 mg/dL. We aimed to estimate the causal effect of glucocorticoids + tocilizumab on mortality overall and...